Oncotarget

Reviews:

Association between the ERCC2 Asp312Asn polymorphism and risk of cancer

Feifan Xiao, Jian Pu, Qiongxian Wen, Qin Huang, Qinle Zhang, Birong Huang, Shanshan Huang, Aihua Lan, Yuening Zhang, Jiatong Li, Dong Zhao, Jing Shen, Huayu Wu, Yan He, Hongtao Li and Xiaoli Yang _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:48488-48506. https://doi.org/10.18632/oncotarget.17290

Metrics: PDF 683 views  |   HTML 930 views  |   ?  


Abstract

Feifan Xiao1,2,*, Jian Pu3,*, Qiongxian Wen4,*, Qin Huang5,*, Qinle Zhang6,*, Birong Huang1,2, Shanshan Huang1,2, Aihua Lan1,2, Yuening Zhang1, Jiatong Li1, Dong Zhao1, Jing Shen1, Huayu Wu7, Yan He8, Hongtao Li1 and Xiaoli Yang1

1Medical Scientific Research Center, Guangxi Medical University, Nanning, Guangxi, P.R. China

2First Clinical Academy, Guangxi Medical University, Nanning, Guangxi, P.R. China

3Liver and Gall Surgical Department, The Affiliated Hospital of Youjiang Medical College for Nationalities, Baise, Guangxi, P.R. China

4School of Nursing, The Second Affiliated Hospital of Guilin Medical University, Guilin, Guangxi, P.R. China

5Guangxi Key Laboratory of Chemistry and Engineering of Forest Products, Guangxi University for Nationalities, Nanning, Guangxi, P.R. China

6Genetic and Metabolic Central Laboratory, The Maternal and Children Health Hospital of Guangxi, Nanning, Guangxi, P.R. China

7Department of Cell Biology and Genetics, School of Premedical Sciences, Guangxi Medical University, Nanning, Guangxi, P.R. China

8Geriatrics Cardiology Division, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P.R. China

*These authors have contributed equally to this work and should be considered as co-first authors

Correspondence to:

Xiaoli Yang, email: cncsyxl@126.com

Keywords: ERCC2 Asp312Asn, polymorphism, cancer, meta-analysis, trial sequence analysis

Received: September 23, 2016     Accepted: April 04, 2017     Published: April 20, 2017

ABSTRACT

Cancer is the leading cause of death in economically developed countries and the second leading cause of death in developing countries. The relationship between genetic polymorphisms and the risk of cancers has been widely researched. Excision repair cross-complementing group 2 (ERCC2) gene plays important roles in the nucleotide excision repair pathway. There is contrasting evidence on the association between the ERCC2 Asp312Asn polymorphism and the risk of cancer. We conducted a comprehensive meta-analysis in order to assess the correlation between these factors. We searched the PubMed, EMBASE, Science Direct, Web of Science, and CNKI databases for studies published from January 1, 2005 to January 1, 2016. Finally, 86 articles with 38,848 cases and 48,928 controls were included in the analysis. The overall analysis suggested a significant association between the ERCC2 Asp312Asn polymorphism and cancer risk. Furthermore, control source, ethnicity, genotyping method, and cancer type were used for subgroup analysis. The result of a trial sequential analysis indicated that the cumulative evidence is adequate; hence, further trials were unnecessary in the overall analysis for homozygote comparison. In summary, our results suggested that ERCC2 Asp312Asn polymorphism is associated with increased cancer risk. A significantly increased cancer risk was observed in Asian populations, but not in Caucasian populations. Furthermore, the ERCC2 Asp312Asn polymorphism is associated with bladder, esophageal, and gastric cancers, but not with breast, head and neck, lung, prostate, and skin cancers, and non-Hodgkin lymphoma. Further multi-center, well-designed studies are required to validate our results.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17290